EGFR and neoplasm: However, in cohort 2, the frequency of EGFR sensitizing mutation and T790M resistance mutation in G1 (10%~19% tumor cellularity ) was significantly lower than in G2 (20%~30% tumor cellularity) and G3 (>30% tumor cellularity).